Q-omics provides the consensus-scored PARK7 profile across patient tissues and cancer cell-line models. PARK7 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PARK7 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, PARK7 protein abundance shows 29,460 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KICH, and HNSC as cancer lineages where PARK7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARK7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARK7 survival associations across molecular data types. PARK7 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARK7 RNA expression–survival associations across cancer types. High PARK7 expression shows unfavorable associations in KICH, HNSC, ACC, UVM, LAML and DLBC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for PARK7 RNA expression.
This table summarizes PARK7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in KICH for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PARK7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARK7 shows lower tumor expression in KICH and THCA and higher tumor expression in COAD, LIHC, LUAD and HNSC. The KICH box plot shows higher PARK7 RNA expression in normal versus tumor tissue (log2 FC = −1.428, t-test p < 0.001).
This table shows molecular features associated with PARK7 in patient tissues and cancer cell lines. In patient samples, PARK7 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, PARK7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and UPPER_AERODIGESTIVE_TRACT.
